Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Dendritic cell-based immunotherapy for prostate cancer Jahnisch H; Fussel S; Kiessling A; Wehner R; Zastrow S; Bachmann M; Rieber EP; Wirth MP; Schmitz MClin Dev Immunol 2010[]; 2010 (ä): 517493Dendritic cells (DCs) are professional antigen-presenting cells (APCs), which display an extraordinary capacity to induce, sustain, and regulate T-cell responses providing the opportunity of DC-based cancer vaccination strategies. Thus, clinical trials enrolling prostate cancer patients were conducted, which were based on the administration of DCs loaded with tumor-associated antigens. These clinical trials revealed that DC-based immunotherapeutic strategies represent safe and feasible concepts for the induction of immunological and clinical responses in prostate cancer patients. In this context, the administration of the vaccine sipuleucel-T consisting of autologous peripheral blood mononuclear cells including APCs, which were pre-exposed in vitro to the fusion protein PA2024, resulted in a prolonged overall survival among patients with metastatic castration-resistant prostate cancer. In April 2010, sipuleucel-T was approved by the United States Food and Drug Administration for prostate cancer therapy.|*Cancer Vaccines[MESH]|*Immunotherapy, Adoptive[MESH]|Acid Phosphatase/immunology/metabolism[MESH]|Animals[MESH]|Antigen-Presenting Cells/immunology[MESH]|Antigens, Neoplasm/immunology/metabolism[MESH]|Clinical Trials as Topic[MESH]|Dendritic Cells/*immunology[MESH]|Drug Approval[MESH]|Granulocyte-Macrophage Colony-Stimulating Factor/immunology/metabolism[MESH]|Humans[MESH]|Lymphocyte Activation[MESH]|Male[MESH]|Prostatic Neoplasms/*immunology/pathology/*therapy[MESH]|Recombinant Fusion Proteins/immunology/metabolism[MESH]|Tissue Extracts/*therapeutic use[MESH]|United States[MESH] |